These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 18686746

  • 1. Becaplermin gel in the treatment of diabetic neuropathic foot ulcers.
    Papanas N, Maltezos E.
    Clin Interv Aging; 2008; 3(2):233-40. PubMed ID: 18686746
    [Abstract] [Full Text] [Related]

  • 2. Use of Regranex gel for diabetic foot ulcers.
    Piascik P.
    J Am Pharm Assoc (Wash); 1998; 38(5):628-30. PubMed ID: 9782698
    [No Abstract] [Full Text] [Related]

  • 3. Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers.
    Papanas N, Maltezos E.
    Drug Saf; 2010 Jun 01; 33(6):455-61. PubMed ID: 20486728
    [Abstract] [Full Text] [Related]

  • 4. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
    Persson U, Willis M, Odegaard K, Apelqvist J.
    Value Health; 2000 Jun 01; 3 Suppl 1():39-46. PubMed ID: 16464208
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
    Sibbald RG, Torrance G, Hux M, Attard C, Milkovich N.
    Ostomy Wound Manage; 2003 Nov 01; 49(11):76-84. PubMed ID: 14652415
    [Abstract] [Full Text] [Related]

  • 6. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.
    Ghatnekar O, Persson U, Willis M, Odegaard K.
    Pharmacoeconomics; 2001 Nov 01; 19(7):767-78. PubMed ID: 11548912
    [Abstract] [Full Text] [Related]

  • 7. Cost-effective management of recalcitrant diabetic foot ulcers.
    Albert S.
    Clin Podiatr Med Surg; 2002 Oct 01; 19(4):483-91. PubMed ID: 12471856
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
    Wieman TJ, Smiell JM, Su Y.
    Diabetes Care; 1998 May 01; 21(5):822-7. PubMed ID: 9589248
    [Abstract] [Full Text] [Related]

  • 9. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
    Embil JM, Papp K, Sibbald G, Tousignant J, Smiell JM, Wong B, Lau CY.
    Wound Repair Regen; 2000 May 01; 8(3):162-8. PubMed ID: 10886806
    [Abstract] [Full Text] [Related]

  • 10. Clinical trial report stirs debate.
    Magee G, Ovington LG.
    Adv Skin Wound Care; 2006 Mar 01; 19(2):64; author reply 64, 67. PubMed ID: 16557046
    [No Abstract] [Full Text] [Related]

  • 11. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers.
    Miller MS.
    J Foot Ankle Surg; 1999 Mar 01; 38(3):227-31. PubMed ID: 10384364
    [Abstract] [Full Text] [Related]

  • 12. Healing and preventing the diabetic foot wound: where technology, economics and common sense converge.
    Armstrong DG.
    Indian J Med Sci; 2007 Jun 01; 61(6):324-5. PubMed ID: 17558094
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.
    Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH.
    Wound Repair Regen; 1999 Jun 01; 7(5):335-46. PubMed ID: 10564562
    [Abstract] [Full Text] [Related]

  • 14. Immunomodulatory role of Tinospora cordifolia as an adjuvant in surgical treatment of diabetic foot ulcers: a prospective randomized controlled study.
    Purandare H, Supe A.
    Indian J Med Sci; 2007 Jun 01; 61(6):347-55. PubMed ID: 17558098
    [Abstract] [Full Text] [Related]

  • 15. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers.
    Steed DL.
    Plast Reconstr Surg; 2006 Jun 01; 117(7 Suppl):143S-149S; discussion 150S-151S. PubMed ID: 16799381
    [Abstract] [Full Text] [Related]

  • 16. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study.
    Rees RS, Robson MC, Smiell JM, Perry BH.
    Wound Repair Regen; 1999 Jun 01; 7(3):141-7. PubMed ID: 10417749
    [Abstract] [Full Text] [Related]

  • 17. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis.
    Kantor J, Margolis DJ.
    Dermatol Surg; 2001 Apr 01; 27(4):347-51. PubMed ID: 11298704
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of becaplermin gel on wound healing of diabetic foot ulcers.
    Gilligan AM, Waycaster CR, Motley TA.
    Wound Repair Regen; 2015 Apr 01; 23(3):353-60. PubMed ID: 25810233
    [Abstract] [Full Text] [Related]

  • 19. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group.
    Wieman TJ.
    Am J Surg; 1998 Aug 01; 176(2A Suppl):74S-79S. PubMed ID: 9777976
    [Abstract] [Full Text] [Related]

  • 20. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers.
    Nagai MK, Embil JM.
    Expert Opin Biol Ther; 2002 Feb 01; 2(2):211-8. PubMed ID: 11849120
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.